Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapcabtagene autoleucel in difficult-to-treat rheumatoid arthritis and severe refractory Sjogren's disease
2024-514596-18-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Jun 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of rapcabtagene autoleucel in rheumatoid arthritis (RA) and Sjögren's syndrome, sponsored by Novartis. Primary endpoint: Safety parameters. Planned start Jun 2025; status: authorised.
02
Drugs
rapcabtagene autoleucel
03
Conditions
rheumatoid arthritis (RA)Sjögren's syndrome
Beyond the preview
Go deeper on 2024-514596-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514596-18-00.